Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes

INTRODUCTION: A second-generation basal insulin analogue insulin glargine 300 U/mL (Gla-300) has been marketed in France since June 2016. This real-world study was designed to assess persistence with Gla-300 and the prevalence of related hypoglycemia requiring hospitalization as compared to first-ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Roussel, Ronan, Detournay, Bruno, Boultif, Zahra, Bahloul, Amar, Teissier, Clement, Charbonnel, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376764/
https://www.ncbi.nlm.nih.gov/pubmed/32651837
http://dx.doi.org/10.1007/s13300-020-00874-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376764/
https://www.ncbi.nlm.nih.gov/pubmed/32651837
http://dx.doi.org/10.1007/s13300-020-00874-2

Ejemplares similares